

COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except for share and per share amounts)

	Three Months Ended December 31,		Year Ended December 31,	
	2018	2017	2018	2017
	Unaudited	Unaudited		
Revenues	-	-	17,800	-
Cost of revenues	-	-	1,034	-
Gross profit	-	-	16,766	-
Operating expenses				
Research and development expenses	7,464	7,170	30,318	28,583
Marketing and business development expenses	245	291	1,634	1,189
General and administrative expenses	1,967	1,925	8,041	7,633
Total operating expenses	9,676	9,386	39,993	37,405
Operating loss	(9,676)	(9,386)	(23,227)	(37,405)
Financial and other income, net	277	76	628	339
Loss before taxes on income	(9,399)	(9,310)	(22,599)	(37,066)
Taxes on income	-	-	-	-
Net loss	(9,399)	(9,310)	(22,599)	(37,066)
Basic and diluted net loss per ordinary share	(0.16)	(0.18)	(0.41)	(0.72)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	59,542,963	51,290,725	55,277,428	50,179,694

COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars in thousands)

	<u>December 31,</u> 2018	<u>December 31,</u> 2017
ASSETS		
Current assets		
Cash, cash equivalents, short-term bank deposits and restricted cash	45,675	30,438
Other accounts receivable and prepaid expenses	903	741
Total current assets	<u>46,578</u>	<u>31,179</u>
Non-current assets		
Long-term prepaid expenses	776	110
Severance pay fund	2,454	2,810
Property and equipment, net	3,372	4,647
Total non-current assets	<u>6,602</u>	<u>7,567</u>
Total assets	<u>53,180</u>	<u>38,746</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Other accounts payable, accrued expenses and trade payables	8,900	6,194
Deferred participation in R&D expenses	1,089	-
Total current liabilities	<u>9,989</u>	<u>6,194</u>
Non-current liabilities		
Long-term deferred participation in R&D expenses	3,003	-
Accrued severance pay	2,945	3,255
Total non-current liabilities	<u>5,948</u>	<u>3,255</u>
Total shareholders' equity	<u>37,243</u>	<u>29,297</u>
Total liabilities and shareholders' equity	<u>53,180</u>	<u>38,746</u>